1164. In vitro Activity of Ceftaroline Against Skin and Soft Tissue and Respiratory Pathogens Isolated from Latin America
Session: Poster Abstract Session: Clinical Infectious Diseases: Bone and Joint, Skin and Soft Tissue
Friday, October 28, 2016
Room: Poster Hall
Posters
  • AZ_P2_CPT_LATAM_IDSA2016_v01 final.pdf (713.0 kB)
  • Background: Ceftaroline is a cephalosporin with in vitro activity against both gram-positive and gram-negative pathogens, including methicillin-resistant S. aureus (MRSA).  This analysis was conducted to evaluate the activity of this compound against key bacterial groups collected from Latin America. Methods: ESBL-negative Enterobacteriaceae, S. aureus (MSSA and MRSA), and S. pneumoniae from skin and soft tissue and respiratory specimens were collected during 2012 – 2014 from across six countries.  The identification of all organisms was confirmed centrally by MALDI-TOF and broth microdilution susceptibility testing and interpretation was performed according to CLSI M100 and M7 guidelines. Results: Ceftaroline activity was recorded based on % susceptibility (%S) and MIC90 in the table provided.  Against S. aureus, all MSSA were susceptible (MIC ≤ 1 mg/ml), only one MRSA isolate (from Venezuela) was resistant with an MIC of 4 mg/ml.; all other non-susceptible MRSA isolates were intermediate with an MIC of 2 mg/ml.

    Table 1. In vitro Activity of Ceftaroline

     

    Argentina

    Brazil

    Chile

    Colombia

    Mexico

    Venezuela

     

    n

    %S/MIC90

    n

    %S/MIC90

    n

    %S/MIC90

    n

    %S/MIC90

    n

    %S/MIC90

    n

    %S/MIC90

    S. aureus, MRSA

    474

    93.0/1

    144

    79.2/2

    393

    29.5/2

    115

    95.7/1

    505

    98.4/1

    418

    90.4/1

    S. aureus, MSSA

    273

    100/0.25

    150

    100/0.25

    313

    100/0.25

    163

    100/0.25

    338

    100/0.25

    281

    100/0.25

    S. pneumoniae

    110

    100/0.12

    13

    100/0.12

    84

    100/0.12

    18

    100/0.06

    83

    100/0.12

    62

    100/0.12

    ESBL-negative Enterobacteriaceae

    247

    85.4/2

    114

    86.8/1

    157

    87.3/1

    120

    89.2/1

    401

    90.3/0.5

    255

    91.8/0.5

    Conclusion: Based on these data generated with isolates collected from 2012 - 2014 ceftaroline continued to exhibit potent in vitro activity against the major bacterial species associated with skin and soft tissue infections and respiratory infections in Latin America. Nearly all non-susceptibility among MRSA to ceftaroline was due to isolates being intermediate with MICs of 2 mg/ml

                                                                                                                                          

     

    Douglas Biedenbach, MS1, Meredith Hackel, PhD, MPH1, Joseph Iaconis, PhD2 and Dan Sahm, PhD1, (1)International Health Management Associates, Inc., Schaumburg, IL, (2)AstraZeneca Pharmaceuticals, Waltham, MA

    Disclosures:

    D. Biedenbach, IHMA, Inc.: Independent Contractor , Research support

    M. Hackel, IHMA, Inc.: Independent Contractor , Research support

    J. Iaconis, AstraZeneca Pharmaceuticals: Employee , Salary

    D. Sahm, IHMA, Inc.: Independent Contractor , Research support

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.